Markets:

Overview

News

Currencies

International

Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.8999 -0.0001 (-0.01%)

Streaming Delayed Price Updated: 3:59 PM EST, Jan 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 Next >

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

January 14, 2026

Via ACCESS Newswire

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 12, 2026

Via ACCESS Newswire

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

January 07, 2026

Via ACCESS Newswire

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

December 01, 2025

Via ACCESS Newswire

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

November 20, 2025

Via ACCESS Newswire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

November 06, 2025

Via ACCESS Newswire

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

October 29, 2025

Via ACCESS Newswire

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

October 15, 2025

Via ACCESS Newswire

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

September 11, 2025

Via ACCESS Newswire

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

September 10, 2025

Via ACCESS Newswire

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

September 09, 2025

Via ACCESS Newswire

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

September 09, 2025

Via ACCESS Newswire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

August 08, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

July 24, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

July 16, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

July 01, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

May 08, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

April 29, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

March 17, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

March 13, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

March 06, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

February 26, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

February 24, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

January 24, 2025

From Revelation Biosciences Inc.

Via Business Wire

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

January 21, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

January 13, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

January 06, 2025

From Revelation Biosciences, Inc.

Via Business Wire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.